Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.

GILEAD | Medical Information

Epclusa® (sofosbuvir/velpatasvir) SVR4 and SVR24

This document is in response to your request for information regarding the use of Epclusa® (sofosbuvir/velpatasvir [SOF/VEL]) and data on sustained virologic response 4 weeks after end of treatment (SVR4) and sustained virologic response 24 weeks after end of treatment (SVR24) from phase 3 clinical studies.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.

Product Labeling[1]

There is no information in the SOF/VEL product labeling regarding SVR4 and SVR24. SVR12, defined as HCV RNA less than the lower level of quantification at 12 weeks after the end of treatment, was the primary endpoint in all the clinical trials.

Clinical Data on SOF/VEL Use and SVR4 or SVR24

ASTRAL Studies

Five phase 3 registrational studies evaluated the efficacy and safety of SOF/VEL. ASTRAL-1, -2, and -3 evaluated the efficacy and safety of SOF/VEL in 1035 participants with HCV GT 1 through 6, including treatment-experienced participants (28%) and those with compensated cirrhosis (21%).[2-4]

ASTRAL-4 evaluated SOF/VEL ± RBV in 267 participants with decompensated cirrhosis (classified as Child-Pugh-Turcotte Class B). ASTRAL-5 evaluated 12 weeks of SOF/VEL treatment in 106 treatment-naive or treatment-experienced participants with HCV GT 1 through 4 who also had HIV.[2-4]

POLARIS Studies

Three phase 3 registrational studies evaluated the efficacy and safety of SOF/VEL/VOX compared with SOF/VEL. POLARIS-2 and POLARIS-3 evaluated 12 weeks of SOF/VEL treatment in 549 participants with GT 1 through 6 ± cirrhosis who were DAA-naive. POLARIS-4 evaluated 12 weeks of SOF/VEL treatment in 151 participants with GT 1 through 4 ± cirrhosis who were DAA treatment-experienced with a regimen that did not contain an NS5A inhibitor.[5,6]

Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.

Pooled ASTRAL and POLARIS Data

Table 1. ASTRAL and POLARIS: SOF/VEL Use and SVR4, SVR12, and SVR24[3,7-11]

Study	ClinicalTrials.gov Identifier	SVR4, % (95% CI)	SVR12, % (95% CI)	SVR24, % (95% CI)
ASTRAL-1	NCT02201940	99.2 (98.1–99.7)	99 (97.9–99.6)	99 (97.9–99.6)
ASTRAL-2	NCT02220998	99.3 (95.9–100)	99.3 (95.9–100)	99.3 (95.9–100)
ASTRAL-3	NCT02201953	96.8 (93.9–98.5)	95.3 (92.1–97.5)	95.3 (92.1–97.5)
ASTRAL-4	NCT02201901	-	-	-
12 weeks	-	92.2 (84.6–96.8)	83.3 (74–90.4)	83.3 (74–90.4)
12 weeks + RBV	-	95.4 (88.6–98.7)	94.3 (87.1–98.1)	94.3 (87.1–98.1)
24 weeks	-	90 (81.9–95.3)	87.8 (79.2–93.7)	87.8 (79.2–93.7)
ASTRAL-5	NCT02480712	95.3 (89.3–98.5)	95.3 (89.3–98.5)	95.3 (89.3–98.5)
POLARIS-2	NCT02607800	98.9 (97.4–99.6)	98.2 (96.4–99.2)	98 (96.2–99.1)
POLARIS-3	NCT02639338	97.2 (92.2–99.4)	96.3 (90.9–99)	96.3 (90.9–99)
POLARIS-4	NCT02639247	91.4 (85.7–95.3)	90.1 (84.1–94.3)	90.1 (84.1–94.3)

Integrated safety analysis

A retrospective integrated analysis of the ASTRAL-1, -2, -3, and 5, POLARIS-2 and -3, Russian and Swedish (Chulanov et al[12]), and Indian (Sood et al[13]) studies was conducted to evaluate the efficacy and safety of 12 weeks of SOF/VEL for HCV treatment. Patients with decompensated cirrhosis were excluded from this analysis.[14] A summary of safety data is provided in Table 2.

Table 2. ASTRAL-1, -2, -3, and -5 and POLARIS-2 and -3: Integrated Safety Summary[14]

Safety Parameters, n (%)		SOF/VEL (N=1938)
AEs		1352 (70)
Treatment-emergent AEs occurring in ≥5% of patients	Headache	464 (24)
	Fatigue	376 (19)
	Nausea	199 (10)
	Nasopharyngitis	149 (8)
	Insomnia	122 (6)
	Diarrhea	120 (6)
	Asthenia	99 (5)
Serious AEs		40 (2)
Grade 3 or 4 AEs		56 (3)
Grade 3 or 4 laboratory abnormalities		139 (7)
Discontinued due to AEs		7 (<1)
Deaths		4 (<1)

Abbreviation: AE=adverse event.

Guidelines on Assessing SVR

Per AASLD guidelines, “Undetectable or unquantifiable HCV RNA 12 weeks or longer after treatment completion is defined as an SVR, which is consistent with cure of hepatitis C infection.”[15]

Intended for U.S. Healthcare Professionals only
Last Updated: 20 Aug 2026

In their Guidance for Industry, the US Department of Health and Human Services (HHS) FDA Center for Drug Evaluation and Research (CDER) states that antiviral treatment efficacy refers to SVR assessed 12 weeks after end of treatment.[16]

References

1. Enclosed. Gilead Sciences Inc, EPCLUSA® (sofosbuvir and velpatasvir) tablets, for oral use. US Prescribing Information. Foster City, CA.
2. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. *N Engl J Med.* 2015;373(27):2599-2607.
3. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med.* 2015.
4. Wyles D, Brau N, Kottilil S, et al. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected with Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. *Clin Infect Dis.* 2017;65(1):6-12.
5. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. *Gastroenterology.* 2017;153(1):113-122.
6. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med.* 2017;376(22):2134-2146.
7. Gilead Sciences Inc. Data on File.
8. ClinicalTrials.gov. Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis (ASTRAL-4). Available at: https://clinicaltrials.gov/study/NCT02201901?term=NCT02201901&rank=1&tab=results.
9. ClinicalTrials.gov. Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2). Available at: https://clinicaltrials.gov/study/NCT02607800?term=NCT02607800&rank=1&tab=results.
10. ClinicalTrials.gov. Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3). Available at: https://clinicaltrials.gov/study/NCT02639338?term=NCT02639338&rank=1&tab=results.
11. ClinicalTrials.gov. Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4). Available at: https://clinicaltrials.gov/study/NCT02639247?term=NCT02639247&rank=1&tab=results.
12. Chulanov V, Weiland O, Zhdanov K, et al. Sofosbuvir/Velpatasvir Is Safe and Effective in a Phase 3 Study of Genotype 1–3 HCV-infected Russian and Swedish Patients [Presentation]. Paper presented at: 27th Annual Conference of the Asian Pacific Association for The Study of the Liver (APASL); 14-18 March, 2018; New Delhi, India.
13. Sood A, Duseja A, Kabrawala M, et al. The Sofosbuvir/Velpatasvir Single Tablet Regimen Administered for 12 Weeks with Minimal Monitoring in India [Presentation] Paper presented at: Asian Pacific Association for The Study of the Liver (APASL); 14-18 March, 2018; New Delhi, India.
14. Shafran S, Feld J, Jacobson I, et al. Sofosbuvir/Velpatasvir, a Pangenotypic Single-Tablet Regimen: Integrated Analysis of Phase 3 Clinical Trials in Genotypes 1-6 [Poster Number 23]. Paper presented at: International Viral Hepatitis Elimination Meeting (IVHEM); 07-08 December, 2018; Amsterdam, the Netherlands.
15. American Association for the Study of Liver Diseases (AASLD). *HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Last Updated: 06 November.* 2019.
16. U. S. Department of Health and Human Services (DHHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). *Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry. DRAFT GUIDANCE. Rockville, MD.* May 2016.

Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.

Abbreviations

AASLD=American Association for the Study of Liver Diseases
DAA=direct-acting antiviral
GT=genotype
RBV=ribavirin
SOF=sofosbuvir
SVR=sustained virologic response
SVR4/12/24=sustained virologic response 4/12/24 weeks after end of treatment
VEL=velpatasvir
VOX=voxilaprevir

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Epclusa US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or 🖱 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.

EPCLUSA, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
© 2026 Gilead Sciences, Inc.